Cash, cash equivalents and marketable securities were $210.4M on April 30, 2024, vs. $149.4M on April 30, 2023. “This last fiscal quarter was the most important in the history of KalVista,” said CEO Ben Palleiko. “Not only did we submit the NDA for sebetralstat to the FDA, but the KONFIDENT phase 3 trial results were published in The New England Journal of Medicine, supporting our view on the importance of this potential therapy. We look forward to building on these milestones as we submit additional marketing authorization applications to other national health authorities throughout 2024 and anticipate approval and launch in the US in the first half of 2025.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- KalVista reports inducement grants under Nasdaq listing rule
- Is KALV a Buy, Before Earnings?
- KalVista begins trial for sebetralstat in children with hereditary angioedema
- KalVista submits New Drug Application to FDA for sebetralstat
- KalVista presents data on persisting unmet needs in Hereditary Angioedema